Trial Filter
BETAAn intelligent search tool for clinical trials
Official Title
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Phase
Phase 3
Sponsor
SWOG Cancer Research Network
Enrollment
491
Timeline
Nov 2017 → Sep 2027
About This Study
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
Eligibility Criteria
Inclusion Criteria
- 1STEP 1 REGISTRATION
- 2Patients must:
- 3Have metastatic breast cancer, AND
- 4Be initiating within 11 calendar days of Step 1 Registration OR be continuing trastuzumab-based HER-2 targeted therapy without concurrent anthracyclines, AND
- 5Be receiving the trastuzumab-based HER-2 targeted therapy for metastatic disease in first, second, third-, or fourth-line setting. Patients may have brain metastasis. There is no limit for number of doses of HER-2 targeted therapy prior to registration.
- 6Examples of eligible HER-2 targeted therapy:
- 7Trastuzumab or a trastuzumab biosimilar
- 8Trastuzumab + chemotherapy or hormonal therapy
- 9Trastuzumab + other HER-2 targeted agent with or without chemotherapy (such as pertuzumab, lapatinib, and tucatinib)
- 10Ado-trastuzumab (Kadcyla®)
- 11Fam-trastuzumab deruxtecan (Enhertu) NOTE: Patients on lapatinib without trastuzumab are not eligible. Planned treatment with concurrent HER-2 targeted therapy and anthracyclines is not permitted.
- 12Patients must be at increased risk for cardiotoxicity defined by at least one of the following:
- 13Previous anthracycline exposure OR
- 141 or more of the following risk factors for heart disease:
- 15LVEF 50-54% by local ECHO read\*
- 16Age ≥ 65
- 17BMI ≥ 30 kg/m2
- 18Current or prior anti-hypertensive therapy
- 19Diagnosis of coronary artery disease (CAD)
- 20Diagnosis of diabetes mellitus
- 21Diagnosis of atrial fibrillation/flutter Note: ECHO can be performed at any time prior to registration with the most recent being sent.
- 22Patients must not have taken within 21 days prior to Step 1 Registration, be currently taking at the time of Step 1 Registration or planning to take once registered to Step 1 a beta blocker, ARB, or ACE inhibitor, in order to be randomized (Arms 1 and 2).
- 23Patients enrolling in the observational cohort (Arm 3) must be currently taking a beta blocker, ARB, or ACE inhibitor at the time of Step 1 Registration.
- 24Patients must have a Zubrod Performance status of 0-2
- 25Patients must have a complete physical examination and medical history within 28 days prior to registration
- 26Patients must have LVEF \>= 50% echocardiogram (2D or 3D) within 28 days prior to registration. The echocardiogram must be obtained from a S1501 validated ECHO laboratory (lab) and submitted for central review by the S1501 ECHO core lab.
- 27If a 3D echocardiogram is performed at baseline, sites must ensure that standard 2D images, including 40chamber and 2-chamber views, are also obtained and submitted at subsequent timepoints.
- 28All follow-up echocardiograms (every 12 weeks) must be performed using 2D imaging to allow for standardized assessments. Follow-up scans must be completed at a site that can provide 2D images per protocol requirements. The echocardiograms cannot be submitted for central read until after Step 1 registration is complete.
- 29Patients must have adequate hepatic function as evidenced by all of the following within 28 days prior to registration:
- 30Serum bilirubin \< 3.0 x institutional upper limit of normal (IULN)
- 31Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) \< 5.0 x IULN
- 32Patients must not be dialysis dependent
- 33No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer on active surveillance, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
- 34Patients must not be pregnant or nursing due to potential fetal or nursing infant harm; women/men of reproductive potential must have agreed to use an effective contraceptive method, a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
- 35Patients must be willing to submit blood specimens
- 36Sites must seek additional patient consent for the future use of specimens
- 37Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- 38For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and CIRB regulations.
- 39As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- 40STEP 2 REGISTRATION (Randomization)
- 41Patients must not be registered to step 2 until confirming via RAVE EDC that the patient's LVEF by echocardiogram was \>= 50% by central review. Patients must be registered within 21 calendar days of submission of the ECHO study/
- 42Site must verify that there is no known change in the step 1 eligibility since initial registration
Locations
590 sites participating in this study
Emory University Hospital Midtown
Atlanta, Georgia 30308
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
Kevin M. Kalinsky
Emory Saint Joseph's Hospital
Atlanta, Georgia 30342
Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →